Medical/Pharmaceuticals
Metabolon Partners with China Kadoorie Biobank to Advance Precision Health
The landmark multiomics study will examine how lifestyle, environmental,
socioeconomic, and genetic factors play a significant role in shaping common
diseases
MORRISVILLE, N.C., Sept. 9, 2025 /PRNewswire/ -- Metabolon
2025-09-09 21:00
1529
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
2025-09-09 20:42
2712
Elevating Healthcare Innovation: ICP DAS-BMP Brings Advanced TPU Portfolio at Medtec China 2025
HSINCHU, Sept. 9, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in Medtec China 2025, to be held fromSeptember 24 to 26 at the Shanghai World Expo Exhibit...
2025-09-09 09:45
2295
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of minimally invasive interventional oncology solutions, today announced that it has received an...
2025-09-08 21:00
1309
SpaceGut's Precision AI System for Gut Testing Achieves Up to 87% Improvement in Irritable Bowel Syndrome Management
KUALA LUMPUR, Malaysia, Sept. 8, 2025 /PRNewswire/ -- SpaceGut
2025-09-08 20:37
1944
FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials
This milestone opens a path for FibroScan® to ultimately replace liver biopsy
for patient enrollment and treatment response assessment in MASH drug
development
WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens
2025-09-08 18:00
1273
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
* Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company * KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA * Acquisition strengthens ...
2025-09-08 15:49
910
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion
GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue ofRMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year...
2025-09-08 15:35
5214
Siriraj × MIT Hacking Medicine 2025 Now Open for Applications Across Southeast Asia: A Call for Innovation to Tackle Greatest Healthcare Challenges
BANGKOK, Sept. 8, 2025 /PRNewswire/ -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place fromOctober 31 to November 2, 2025. Applications are now open for part...
2025-09-08 14:39
2383
Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC
HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor ty...
2025-09-05 21:38
2736
'CART BP pro' Opens a New Paradigm in Blood Pressure Management, Maintaining Accuracy Across Arm Positions
SEOUL, South Korea, Sept. 5, 2025 /PRNewswire/ -- At the European Society of Cardiology (ESC) Congress 2025, held inMadrid from August 29 to September 1, Sky Labs presented new clinical findings on CART BP pro, its cuffless, ring-type blood pressure monitor. The device demonstrated consistent acc...
2025-09-05 20:48
2582
FUTUONING Sets Sail Commercially with First Prescriptions Across China
SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals acrossChina, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Af...
2025-09-05 18:12
3148
Olympus Announces Distribution Partnership with MacroLux Medical for Single-Use Urology Products
WESTBOROUGH, Mass., Sept. 4, 2025 /PRNewswire/ -- Olympus Corp., a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today an exclusive global distribution agreement with MacroLux Medical Technology Co., Ltd. to distribute single-...
2025-09-04 22:12
1686
Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. Jared Bearss...
2025-09-04 20:00
1451
Sentec Receives FDA Clearance for LuMon™ Electrical Impedance Tomography (EIT) System -- First EIT System Indicated for Premature Infants and for Spontaneously Breathing Patients in the United States
The LuMon™ System is also CE-marked under EU MDR and registered with TGA in Australia. LINCOLN, R.I., Sept. 4, 2025 /PRNewswire/ -- Sentec, a global leader in non-invasive patient monitoring, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Lu...
2025-09-04 19:00
1432
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
Medicare confirms reimbursement, unlocking nationwide access to non-contrast ventilation–perfusion imaging from routine chest CT LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in advanced respiratory imaging, today announces U.S. Food and Drug Administration (FDA) 510(k) clearanc...
2025-09-04 18:00
1612
UNSW and NeuRA Lead New Study to Explore How ReNeuWell® App Supports Mental Wellbeing
SYDNEY, Sept. 4, 2025 /PRNewswire/ -- A clinical trial is being launched by
researchers from UNSW and Neuroscience Research Australian (NeuRA) for a new
app called ReNeuWell®, based on a scientifically validated measure of wellbeing.
2025-09-04 06:23
2111
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumin...
2025-09-03 21:15
1725
SPS Expands Philips SpeechLive with Ambient Medical AI Documentation, Powered by Corti
VIENNA, Austria and COPENHAGEN, Denmark, Sept. 3, 2025 /PRNewswire/ -- Speech Processing Solutions (SPS), the global leader behind Philips SpeechLive, today announced a strategic partnership with Corti, the specialized AI infrastructure company for healthcare, to introduce ambient clinical docume...
2025-09-03 20:53
1331
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 ...
2025-09-02 21:10
2866
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8349